Perkins Capital Management’s Fortress Biotech FBIO Stock Holding History

Perkins Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-93,768	Closed	-$408K	–	94
2023 Q3	$408K	Sell	93,768 -833	-0.9%	-$5.71K	0.4%	65
2023 Q2	$780K	Hold	94,601	–	–	0.68%	45
2023 Q1	$1.16M	Buy	94,601 +39,767	+73%	+$474K	1.1%	35
2022 Q4	$539K	Buy	54,834 +2,000	+4%	+$22.1K	0.57%	50
2022 Q3	$682K	Buy	52,834 +2,101	+4%	+$31.5K	0.76%	42
2022 Q2	$639K	Buy	50,733 +43,879	+640%	+$650K	0.66%	49
2022 Q1	$140K	Hold	6,854	–	–	0.11%	94
2021 Q4	$257K	Sell	6,854 -1,733	-20%	-$77.3K	0.17%	87
2021 Q3	$415K	Hold	8,587	–	–	0.26%	77
2021 Q2	$460K	Buy	8,587 +98	+1%	+$5.91K	0.26%	79
2021 Q1	$449K	Buy	+8,489	New	+$479K	0.26%	79

Other funds holding FBIO

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Perkins Capital Management's FBIO Position: Q4 2023 in Review

Perkins Capital Management sold out of Fortress Biotech (FBIO) in Q4 2023, closing a stake of 93,768 shares — an estimated $408K sold.

Perkins Capital Management first reported a position in FBIO in Q1 2021 and held it in 11 quarters. The position peaked at $1.16M in Q1 2023. 42 funds tracked by Wall St. Rank hold FBIO as of Q4 2023.

Perkins Capital Management reported no remaining Fortress Biotech position as of Q4 2023 after selling out during the quarter.
Perkins Capital Management sold 93,768 Fortress Biotech shares in Q4 2023, an estimated $408K.
Perkins Capital Management first reported a position in Fortress Biotech in Q1 2021 and held it in 11 quarters.
Perkins Capital Management's Fortress Biotech position peaked at $1.16M in Q1 2023.
42 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2023.

Based on Perkins Capital Management's 13F filing for Q4 2023, filed 22 Jan 2024.